MALVERN, UK - Malvern Instruments Ltd., Malvern, UK, has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC, Santa Barbara, CA. Both of these developments extend Malvern’s portfolio of analytical solutions for the rapidly advancing biopharmaceutical industry.

The agreement to purchase GE Healthcare Life Sciences’ MicroCal business was announced on June 4, 2014 by Malvern’s parent company Spectris plc. MicroCal microcalorimeters are now part of the Malvern Instruments portfolio and are being sold and supported by Malvern Instruments with immediate effect.

Malvern’s purchase of the Archimedes product from Affinity Biosensors follows two years of collaborative working between the two companies. In 2012, Malvern entered into an exclusive distribution agreement with Affinity Biosensors to market and sell Affinity Biosensors’ Archimedes particle characterization system in all geographies outside of North America, with a co-marketing agreement for North America itself. Malvern has now acquired the Archimedes product designs and IP and a license to the underlying MIT patent for the technology for relevant fields of use. With this complete, Archimedes becomes a fully Malvern owned product and continues to be supported by the Malvern teams worldwide.